These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33581779)

  • 1. Impact of estimated-weight-base dose of alteplase in acute stroke treatment on clinical outcome.
    Cheng CY; Chen SH; Chen HM; Li CJ; Liu TY; Tan TY
    J Clin Neurosci; 2021 Mar; 85():101-105. PubMed ID: 33581779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing errors did not have a major impact on outcome in the NINDS t-PA stroke study.
    Messé SR; Kasner SE; Cucchiara BL; Demchuk A; Tanne D; Ouyang B; Levine SR;
    J Stroke Cerebrovasc Dis; 2011; 20(3):236-40. PubMed ID: 20656508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Discrepancy between Measured versus Stated Weight on Hemorrhagic Transformation and Clinical Outcomes after Intravenous Alteplase Thrombolysis.
    Shin DH; Kang MJ; Kim JW; Shin DJ; Park HM; Sung YH; Kim EY
    Cerebrovasc Dis; 2017; 44(5-6):241-247. PubMed ID: 28848080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed Dose IV rt-PA and Clinical Outcome in Ischemic Stroke Patients With Body Weight >100 kg: Pooled Data From 3 Randomized Clinical Trials.
    Majidi S; Leon Guerrero CR; Burger KM; Sigounas D; Olan WJ; Qureshi AI
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2843-2848. PubMed ID: 30076113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage.
    Liu M; Pan Y; Zhou L; Wang Y
    Neurol Res; 2019 May; 41(5):473-479. PubMed ID: 30822264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing of tissue plasminogen activator often differs from 0.9 mg/kg, but does not affect the outcome.
    Aulicky P; Rabinstein A; Seet RC; Neumann J; Mikulik R
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1293-7. PubMed ID: 23246191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI.
    Guo C; Bai Q; Zhao Z; Zhang J
    Cerebrovasc Dis; 2019; 48(1-2):85-90. PubMed ID: 31587000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated versus actual weight when dosing rt-PA in acute ischemic stroke: is there a difference?
    Graves A; VerHage A; Richlik B; Makic MB
    J Neurosci Nurs; 2013 Aug; 45(4):180-5. PubMed ID: 23756450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours.
    Deguchi I; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):1033-1040. PubMed ID: 29221968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a new modified intravenous recombinant tissue plasminogen activator (rt-PA) regimen in Chinese patients with acute ischemic stroke: A descriptive retrospective cohort study with subgroup-analysis of different rt-PA dose.
    Luo Y; Li J; Huang L; Liu X; Zhang B; Lin J; Jiang A; Zhao J
    J Clin Neurosci; 2022 Jul; 101():244-251. PubMed ID: 35653882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100 kg on 3-Month Outcomes in Acute Ischemic Stroke.
    Garavaglia J; Sherman J; Yetzer H; Regier M; Smith M
    J Stroke Cerebrovasc Dis; 2017 May; 26(5):1041-1046. PubMed ID: 28129994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility determination for intravenous thrombolysis based on radiology interpretation report of the head CT scan in patients with acute ischemic stroke.
    Hassan AE; Majidi S; Janjua NA; Chaudhry SA; Tekle WG; Grigoryan M; Qureshi AI
    J Neuroimaging; 2014; 24(4):349-53. PubMed ID: 24015702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke.
    Nagaraja N; Tasneem N; Shaban A; Dandapat S; Ahmed U; Policeni B; Olalde H; Shim H; Samaniego EA; Pieper C; Ortega-Gutierrez S; Leira EC; Adams HP
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1403-1411. PubMed ID: 29398533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erroneous body-weight estimation on outcome of thrombolyzed stroke patients.
    Paliwal PR; Sharma AK; Komal Kumar RN; Wong LYH; Chan BPL; Teoh HL; Sharma VK
    J Thromb Thrombolysis; 2020 Nov; 50(4):921-928. PubMed ID: 32337652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?
    Shaltoni HM; Albright KC; Gonzales NR; Weir RU; Khaja AM; Sugg RM; Campbell MS; Cacayorin ED; Grotta JC; Noser EA
    Stroke; 2007 Jan; 38(1):80-4. PubMed ID: 17122433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.